Challenges and opportunities in Drug Screening
0:00 Welcoming & Speaker Overview (Dr. Tatiana Tiago)
1:16 Introduction to Creoptix (Dr. Tatiana Tiago)
4:21 How GCI can address drug discovery challenges
11:35 waveRAPID - the new way of measuring kinetics (Dr. Tatiana Tiago)
15:58 Summary (Dr. Tatiana Tiago)
17:53 Introduction to Domainex (Dr. Tom Mander)
20:03 GCI Hit ID Project (Dr. Trevor Askwith)
25:50 Hit Expansion phase (Dr. Trevor Askwith)
29:23 Summary (Dr. Trevor Askwith)
In this video Dr. Tatiana Tiago, Product Manager at Creoptix, will be discussing the challenges and opportunities in drug screening, as well as introducing you to the Creoptix WAVEsystem and GCI technology. The second part will be presented by our partners from Domainex. Dr. Tom Mander, CEO at Domainex, will introduce the company and how they are supporting the drug discovery process; followed by Dr. Trevor Askwith, Head of Assay Biology at Domainex, who will share how the GCI technology is helping his team tacking fragment library screening.
-------------------------------------------------------
► More about Domainex: https://www.domainex.co.uk
-------------------------------------------------------
► About Creoptix: https://www.creoptix.com/about-us
► Get in touch with us: https://www.creoptix.com/contact
► Follow us on Linkedin: / creo. .
► Follow us on Twitter: / creoptix
-------------------------------------------------------
Creoptix AG
Zugerstrasse 76
8820 Waedenswil
Switzerland
-------------------------------------------------------
Creoptix Inc.
c/o CliftonLarsonAllen LLP
111 South Bedford Street, Ste. 108
MA-01803 Burlington
USA